Profound Medical (NASDAQ:PROF) Price Target Cut to $12.00

Profound Medical (NASDAQ:PROFGet Rating) had its price objective dropped by analysts at Alliance Global Partners from $16.25 to $12.00 in a report released on Tuesday, The Fly reports. The brokerage presently has a “buy” rating on the stock. Alliance Global Partners’ target price points to a potential upside of 73.91% from the company’s current price.

A number of other brokerages have also issued reports on PROF. Zacks Investment Research lowered shares of Profound Medical from a “hold” rating to a “sell” rating in a research report on Saturday, January 22nd. Raymond James set a $22.00 target price on shares of Profound Medical and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Cowen decreased their target price on shares of Profound Medical from $28.00 to $14.00 and set an “outperform” rating on the stock in a research report on Monday, March 7th.

PROF traded up $0.33 on Tuesday, reaching $6.90. The company had a trading volume of 34,046 shares, compared to its average volume of 54,421. Profound Medical has a fifty-two week low of $6.44 and a fifty-two week high of $19.32. The firm has a market cap of $143.38 million, a PE ratio of -4.38 and a beta of 1.11. The firm’s fifty day simple moving average is $8.52.

Profound Medical (NASDAQ:PROFGet Rating) last announced its quarterly earnings results on Thursday, March 3rd. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). Profound Medical had a negative net margin of 446.65% and a negative return on equity of 34.89%. The company had revenue of $1.00 million during the quarter, compared to analyst estimates of $2.80 million. During the same quarter last year, the company posted ($0.38) EPS. Sell-side analysts forecast that Profound Medical will post -1.14 earnings per share for the current year.

Institutional investors have recently modified their holdings of the company. D. E. Shaw & Co. Inc. bought a new stake in shares of Profound Medical during the 4th quarter worth approximately $121,000. Harbor Advisors LLC bought a new stake in shares of Profound Medical during the 4th quarter worth approximately $139,000. CVI Holdings LLC bought a new stake in shares of Profound Medical during the 3rd quarter worth approximately $146,000. Wealth Management Partners LLC bought a new position in Profound Medical in the 1st quarter valued at approximately $230,000. Finally, Millennium Management LLC bought a new position in Profound Medical in the 3rd quarter valued at approximately $426,000. 60.23% of the stock is owned by institutional investors.

About Profound Medical (Get Rating)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland.

Recommended Stories

The Fly logo

Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.